Analyst Gena Wang of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

The "Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis, 2024-2030" report has been added tAndMarkets.com's ...

Analyst Uy Ear from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price ...

Prime Medicine's layoffs are part of a pattern. At least a half-dozen gene-editing companies have laid off staff in the past ...

As of the latest trading close, SRPT, a Healthcare sector stock, is trading -30.90% below its 52-week high but remains 116.69% above its 52-week low. The Average True Range (ATR) (14 days) of 3.67 ...

Originally published in Quest Diagnostics' 2023 Corporate Responsibility Report We continued to grow access to and ...

Recent Transaction Overview On September 30, 2024, Ikarian Capital, LLC (Trades, Portfolio) made a significant adjustment to ...

Capricor competes with established players like Sarepta Therapeutics (NASDAQ: SRPT) and PepGen (NASDAQ: PEPG) in this space.

Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $120.4 which represents a slight increase of $1.64 or 1.38% from the prior close of $118.76. The stock opened at $119.91 ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Precision medicine offers tailored treatments for rare diseases, addressing genetic variations and improving therapeutic ...

The global mucopolysaccharidosis treatment market is estimated to be valued at approximately USD 2.38 billion in 2022. With the rising prevalence of mucopolysaccharidosis (MSP) worldwide, the market ...